Cantor Fitzgerald’s Grace Therapeutics GRCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$215K Hold
100,000
– – ﹤0.01% 602
2026
Q2
$227K Buy
+100,000
New +$277K ﹤0.01% 316

Other funds holding GRCE

Cantor Fitzgerald's GRCE Position: Q3 2026 in Review

Cantor Fitzgerald held its Grace Therapeutics (GRCE) position steady in Q3 2026 at 100,000 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #602.

Cantor Fitzgerald first reported a position in GRCE in Q2 2026 and has held it in 2 quarters since. The position peaked at $227K in Q2 2026. 38 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

  • Cantor Fitzgerald held 100,000 shares of Grace Therapeutics worth $215K as of Q3 2026.
  • Cantor Fitzgerald left its Grace Therapeutics share count unchanged in Q3 2026.
  • Grace Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #602 holding.
  • Cantor Fitzgerald first reported a position in Grace Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Cantor Fitzgerald's Grace Therapeutics position peaked at $227K in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.